An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of huntington’s disease

Journal of Huntington's Disease

Volumn 2, Issue 4, 2013, Pages 443-451

  Wang, Nan ^a   Lu, Xiao Hong ^a   Sandova, Susana V ^a   Yang, X William ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aggregate; C2 8; Huntingtin; Huntington s disease; Preclinical; R6 2

Indexed keywords

ANILIDE; HUNTINGTIN; N (4 BROMOPHENYL) 3 (4 BROMOPHENYLAMINOSULFONYL)BENZAMIDE; N-(4-BROMOPHENYL) 3-(4-BROMOPHENYLAMINOSULFONYL)BENZAMIDE; NEUROPROTECTIVE AGENT; SULFONAMIDE;

AGGREGATE; ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BRAIN; C2-8; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; HUNTINGTON CHOREA; MOTOR ACTIVITY; MOUSE; PATHOLOGY; PRECLINICAL; R6/2; TRANSGENIC MOUSE;

AGGREGATE; C2-8; HUNTINGTIN; HUNTINGTON'S DISEASE; PRECLINICAL; R6/2;

ANILIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; SULFONAMIDES;

EID: 84906922788     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-130074     Document Type: Article

References (13)

1. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:892-7.
2. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S. A small-molecule therapeutic lead for Huntington’s disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A. 2007;104:16685-9.
3. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493-506.
4. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT, 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187-91.
5. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28:6182-95.
6. Menalled L, El-Khodor BF, Patry M, Suárez-Fariñas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D. Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol Dis. 2009;35:319-36.
7. Turner PV, Brabb T, PekowC, Vasbinder MA. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 201;50:600-13.
8. Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, ChesseletMF, YangXW. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci. 2009;29:1962-76.
9. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:41-53.
10. Saudou F, Finkbeiner S, Devys D, GreenbergME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55-66.
11. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805-10.
12. Truant R, Atwal RS, Desmond C, Munsie L, Tran T. "Huntington’s disease: Revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases". Febs J. 2008;275:4252-62.
13. Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One. 2012;7:e49838.